Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.
Duan J, Zhang Y, Chen R, Liang L, Huo Y, Lu S, Zhao J, Hu C, Sun Y, Yang K, Chen M, Yu Y, Ying J, Huang R, Ma X, Leaw S, Bai F, Shen Z, Cai S, Gao D, Wang J, Wang Z. Duan J, et al. Among authors: cai s. Cell Rep Med. 2023 Dec 19;4(12):101302. doi: 10.1016/j.xcrm.2023.101302. Epub 2023 Dec 4. Cell Rep Med. 2023. PMID: 38052215 Free PMC article.
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, Zhu B, Wang S, Zhuo M, Sun J, Wang Q, Bai H, Han J, Tian Y, Lu J, Xu T, Zhao X, Wang G, Cao X, Li F, Wang D, Chen Y, Bai Y, Zhao J, Zhao Z, Zhang Y, Xiong L, He J, Gao S, Wang J. Wang Z, et al. Among authors: cai s. JAMA Oncol. 2019 May 1;5(5):696-702. doi: 10.1001/jamaoncol.2018.7098. JAMA Oncol. 2019. PMID: 30816954 Free PMC article.
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
Wang Z, Duan J, Wang G, Zhao J, Xu J, Han J, Zhao Z, Zhao J, Zhu B, Zhuo M, Sun J, Bai H, Wan R, Wang X, Fei K, Wang S, Zhao X, Zhang Y, Huang M, Huang D, Qi C, Gao C, Bai Y, Dong H, Xiong L, Tian Y, Wang D, Xu C, Wang W, Li J, Hu X, Cai S, Wang J. Wang Z, et al. Among authors: cai s. J Thorac Oncol. 2020 Apr;15(4):556-567. doi: 10.1016/j.jtho.2019.12.001. Epub 2019 Dec 12. J Thorac Oncol. 2020. PMID: 31843683 Free article.
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J. Duan J, et al. Among authors: cai s. JAMA Oncol. 2020 Mar 1;6(3):375-384. doi: 10.1001/jamaoncol.2019.5367. JAMA Oncol. 2020. PMID: 31876895 Free PMC article.
EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.
Bai H, Duan J, Li C, Xie W, Fang W, Xu Y, Wang G, Wan R, Sun J, Xu J, Wang X, Fei K, Zhao Z, Cai S, Zhang L, Wang J, Wang Z. Bai H, et al. Among authors: cai s. J Immunother Cancer. 2020 Dec;8(2):e001315. doi: 10.1136/jitc-2020-001315. J Immunother Cancer. 2020. PMID: 33303576 Free PMC article.
6,548 results